



Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

September 8, 2020

DURHAM, N.C.--(BUSINESS WIRE)--Sep. 8, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Company will participate in the following virtual investor conferences in September.

- Citi 15th Annual BioPharma Conference
 - Date: Thursday, September 10, 2020
 - Time: 9:50 a.m. Eastern Time
 - Panel Discussion: Ophthalmology – Seeing 20/20 in 2020
 - Panelist: Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer

- H.C. Wainwright 22nd Annual Global Investment Conference
 - Date: Tuesday, September 15, 2020
 - Time: 1:30 p.m. Eastern Time
 - Presenter: Richard J. Rubino, Chief Financial Officer
 - Presentation Type: Fireside

- Cantor Global Healthcare Conference
 - Date: Wednesday, September 16, 2020
 - Time: 10:40 a.m. Eastern Time
 - Presenter: Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer
 - Presentation Type: Fireside

The panel and fireside discussions will be webcast live and may be accessed by visiting Aerie's website at <http://investors.aeriepharma.com>. A replay of the webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa[®] (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa[®], the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa[®], including the product label, is available at www.rhopressa.com. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan[®] (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa[®] and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan[®], the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan[®], including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200908005025/en/): <https://www.businesswire.com/news/home/20200908005025/en/>

Media: Tad Heitmann 949-526-8747; theitmann@aeriepharma.com

Investors: Ami Bavishi 908-947-3949; abavishi@aeriepharma.com

Source: Aerie Pharmaceuticals, Inc.